EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieStudienprotokollOpen access

A Novel Therapy With a One-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB‑YOUTH Study): Protocol for a Cluster Randomized Controlled Trial

Yixuan Yang iD, Feiran Zhou iD, Yanfei Ren iD, Fudong Li iD, Qingluan Yang iD, Yuying He iD, Xiaoling Wei iD, Xing Wang iD, Jianfeng Luo iD, Feng Sun iD, Lingyun Shao iD, Jinlan Li iD and 2 more

JMIR Research Protocols · 2026

DOI: 10.2196/89584 ↗

At a glance

Randomisierte kontrollierte Studie in JMIR Research Protocols, 2026. Written by Yixuan Yang and 13 co-authors. Institution: Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infec…. Major MEDLINE topics: Isoniazid, Latent Tuberculosis, Rifampin, Antitubercular Agents. Cited 1 times so far (Crossref); 29 references. The full text is freely available in PubMed Central.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Close contacts of individuals with active pulmonary tuberculosis (TB) face an elevated risk of TB acquisition, necessitating systematic screening for latent TB infection and subsequent TB preventive treatment (TPT). Major TPT regimens require ≥3 months of drug exposure and demonstrate suboptimal safety profiles, significantly compromising treatment completion rates. Therefore, the development of shorter, safer chemoprophylaxis strategies represents a critical need in global TB control. Among close contacts, school-aged children and adolescents constitute the most vulnerable demographic subgroup, warranting prioritized intervention efforts.

Objective

The primary objective of this study is to demonstrate noninferiority of an ultrashort, 1-month TPT regimen of isoniazid plus rifapentine, administered 3 times a week (1H 3 P 3 ) compared with the standard 3-month daily isoniazid plus rifampicin (3HR) regimen in preventing active TB, as measured by the 24-month cumulative incidence of active TB following randomization.

Methods

An investigator-initiated, prospective, multicenter, open-label, noninferiority, cluster-randomized controlled clinical trial is being implemented under the auspices of the national TB control program in China. Close contacts of school pulmonary TB index cases, regardless of diagnostic type, are actively screened for symptoms using interferon-gamma release assays, chest imaging, and sputum molecular diagnostic testing to detect TB infection and exclude active TB. Eligible latent TB infection cases will be randomized in a 1:1 cluster ratio to receive either the standard 3HR regimen or the novel ultrashort 1H 3 P 3 regimen for TPT, with subsequent follow-up for up to 2 years to assess disease progression. The primary composite end point includes microbiologically confirmed TB (sputum culture or molecular diagnostic testing) or clinically diagnosed TB. With 80% power to detect noninferiority (20% margin), the study requires 1760 participants per arm, accounting for cluster design effects.

Results

Recruitment started in September 2023. By the end of December 2025, a total of 2478 participants, comprising 627 index cases, had been enrolled, and recruitment is estimated to continue until September 2026. Data analysis will commence after the 2-year follow-up period, and the results are expected to be published by March 2029.

Conclusions

This cluster randomized controlled trial aims to establish the noninferiority of a novel, ultrashort 1H 3 P 3 regimen compared to the standard 3-month 3HR regimen for preventing active TB in infected school contacts. If successful, this well-tolerated 1-month regimen could significantly improve treatment completion and optimize preventive therapy delivery in high-transmission congregate settings, thereby contributing substantively to global TB control efforts.

Subjects

MeSH terms (MEDLINE)

IsoniazidLatent TuberculosisRifampinAntitubercular AgentsTuberculosis, PulmonaryHumansAdolescentChildRandomized Controlled Trials as TopicDisease ProgressionMulticenter Studies as TopicProspective StudiesContact TracingFemaleMaleEquivalence Trials as TopicDrug Therapy, Combination

Author keywords

TPTadolescent tuberculosisclinical trialclose contactsmycobacteria tuberculosistuberculosis preventive treatment

Substances

IsoniazidRifampinrifapentineAntitubercular Agents

Authors and institutions

  • Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, No.12 Middle Wulum…
  • Clinical Research Department, Shanghai Sci-Tech Inno Center for Infectious & Immunity, Shanghai, Shanghai, China.
  • Institute for Tuberculosis Control, Guizhou Center for Disease Control and Prevention, Guiyang, Guizhou, China.
  • Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
  • Department of Biostatistics, School of Public Health, Fudan University, Shanghai, Shanghai, China.
  • See Acknowledgments.

ORCID profiles: Yixuan Yang, Feiran Zhou, Yanfei Ren, Fudong Li, Qingluan Yang, Yuying He, Xiaoling Wei, Xing Wang, Jianfeng Luo, Feng Sun, Lingyun Shao, Jinlan Li, Qiaoling Ruan, Wenhong Zhang

Cite

APA

Yang, Y., Zhou, F., Ren, Y., Li, F., Yang, Q., He, Y., Wei, X., Wang, X., Luo, J., Sun, F., Shao, L., Li, J., Ruan, Q., & Zhang, W. (2026). A Novel Therapy With a One-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB‑YOUTH Study): Protocol for a Cluster Randomized Controlled Trial. JMIR Research Protocols. https://doi.org/10.2196/89584

Vancouver

Yang Y, Zhou F, Ren Y, Li F, Yang Q, He Y, et al. A Novel Therapy With a One-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB‑YOUTH Study): Protocol for a Cluster Randomized Controlled Trial. JMIR Research Protocols. 2026. doi:10.2196/89584

BibTeX
@article{Yang2026,
  author = {Yang, Yixuan and Zhou, Feiran and Ren, Yanfei and Li, Fudong and Yang, Qingluan and He, Yuying and Wei, Xiaoling and Wang, Xing and Luo, Jianfeng and Sun, Feng and Shao, Lingyun and Li, Jinlan and Ruan, Qiaoling and Zhang, Wenhong},
  title = {A Novel Therapy With a One-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB‑YOUTH Study): Protocol for a Cluster Randomized Controlled Trial},
  journal = {JMIR Research Protocols},
  year = {2026},
  doi = {10.2196/89584}
}
Start for free →